Refinement of established products

Apart from the discovery of new active substances, the refinement of established products capable of enhancing patients’ quality of life is another major focus at Bayer HealthCare. One example is the multiple sclerosis (MS) drug Betaferon®/Betaseron®, which helps to reduce the frequency of MS episodes. Now a new study has found that early treatment can further delay the onset of disability. Our cover illustration shows Sandra Patkovic and Dr. Jürgen Heubach of Bayer HealthCare studying gene activity patterns from patients treated with Betaferon®/Betaseron®. The scientists’ goal is to identify biomarkers of successful treatment with this drug.